Research and Development Expenses Breakdown: Bristol-Myers Squibb Company vs Viridian Therapeutics, Inc.

R&D Spending: Bristol-Myers Squibb vs. Viridian Therapeutics

__timestampBristol-Myers Squibb CompanyViridian Therapeutics, Inc.
Wednesday, January 1, 20144534000000293000
Thursday, January 1, 201559200000001002000
Friday, January 1, 20164940000000888000
Sunday, January 1, 2017641100000019623000
Monday, January 1, 2018634500000030421000
Tuesday, January 1, 2019614800000034794000
Wednesday, January 1, 20201114300000028304000
Friday, January 1, 20211019500000056886000
Saturday, January 1, 20229509000000100894000
Sunday, January 1, 20239299000000159765000
Monday, January 1, 202411159000000
Loading chart...

In pursuit of knowledge

A Decade of Innovation: R&D Spending in Pharmaceuticals

In the ever-evolving landscape of pharmaceuticals, research and development (R&D) expenses are a critical indicator of a company's commitment to innovation. Over the past decade, Bristol-Myers Squibb Company has consistently demonstrated its dedication, with R&D expenses peaking in 2020 at approximately $11 billion, a staggering 145% increase from 2014. This investment underscores their strategic focus on pioneering treatments and therapies.

In contrast, Viridian Therapeutics, Inc., a smaller player in the industry, has shown remarkable growth in its R&D spending. From a modest $293,000 in 2014, their expenses surged to nearly $160 million by 2023, reflecting a robust 54,000% increase. This dramatic rise highlights Viridian's aggressive push towards innovation and development.

These trends reveal a dynamic industry where both established giants and emerging companies are investing heavily in the future of healthcare.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025